Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
NEW YORK, May 22, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular Therapeutics") (NYSEMKT:IMUC) between May 1, 2012 and December 11, 2013. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Central District of California. To get more information go to:
http://www.zlk.com/pslra-sb/immunocellular-therapeutics-ltd?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; (2) as a result of this scheme, the market was led to believe that ImmunoCellular's clinical studies for its product candidate ICT-107 was going well and the Company's share price was artificially inflated.
On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, which had engaged in stock promotion schemes.
If you suffered a loss in ImmunoCellular Therapeutics you have until June 30, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
